REG - IXICO plc - IXICO secures new contract for £3.4 million

IXICOAnnouncement

24/12/2020 07:01

RNS Number : 7387J
  
IXICO plc
  
24 December 2020
  
 

IXICO plc
("IXICO" or the "Company")
 
IXICO secures new contract for £3.4 million
IXICO broadens its rare disease franchise into SCA3, a rare neurodegenerative condition
 
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces it has been awarded a £3.4 million contract to run over c.4.5 years by an existing client for a Spinocerebellar Ataxia type 3 (SCA3) trial. SCA3, also known as Machado-Joseph disease, is a rare, neurodegenerative condition resulting in movement disorders, rigidity, muscular atrophy and paralysis. Currently there is no treatment to slow down or reverse the progressive course of this terminal disease.  
 
For the study, IXICO will provide operational services and advanced AI neuroimaging solutions for volumetric, diffusion and functional magnetic resonance imaging (vMRI, dMRI, rs-fMRI) as well as magnetic resonance spectroscopy (H-MRS) and quantitative susceptibility mapping (QSM). Having singularly focused on neurological disorders since its inception, IXICO has a long and established track record of enabling biopharmaceutical sponsors to realise the full power of neuroimaging in CNS and rare disease clinical trials.
 
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"SCA3 is an area with clear, unmet medical needs and we are delighted to be chosen as the neuroimaging partner in this spinocerebellar ataxia trial.  Neuroimaging, with its unique ability to reveal extraordinary information about the structural and functional characteristics of the human brain is a powerful tool in CNS studies, and we are proud to support our clients in potentially unlocking new insights into disease progression."
 
This contract was included in management's expectations of performance for the current financial year and adds to the Company's strong order book, providing further future revenue visibility. 
 
 
For further information please contact:
 



IXICO plc


+44 (0)20 3763 7498




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 








 




Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0)20 7397 8900




Giles Balleny / Max Gould (Corporate Finance)


 




Michael F Johnson / Russell Kerr (Sales


 








 




Walbrook PR Ltd


+44 (0)20 7933 8780
 




Paul McManus / Lianne Cawthorne /


IXICO@walbrookpr.com




Alice Woodings
 














 
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
 
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
CNTFEDFMDESSEDE